Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares (CANF)
Stock · AMEX · Health Care
$3.4as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$2.9
Industry
Biotechnology: Pharmaceutical Preparations
Fundamentals
- Market cap
- $6.79M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- —
- Avg. volume
- —
Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares Competitors
Chosen by industry and closest market cap.
- CANFCan-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares$3.4▲ 0.89%Market cap $6.79MP/E —
- PCSAProcessa Pharmaceuticals Inc. Common Stock$2.07▼ 1.90%Market cap $7.09MP/E —$1.67$14.24
- ALZNAlzamend Neuro Inc. Common Stock$1.66▼ 0.30%Market cap $6.42MP/E —$0.84$2.68
- TRAWTraws Pharma Inc. Common Stock$0.59▲ 0.00%Market cap $7.18MP/E —$0.4301$3.27
- APUSApimeds Pharmaceuticals US Inc. Common Stock$3.87▼ 1.28%Market cap $7.32MP/E —$3.39$403.1
- APREAprea Therapeutics Inc. Common stock$0.8387▼ 2.48%Market cap $7.40MP/E —$0.548$1.69
- ACXPAcurx Pharmaceuticals Inc. Common Stock$1.45▼ 1.03%Market cap $6.15MP/E —$1.31$8.34
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CANF Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares | $6.79M | — | $3.4 | ▲ 0.89% | |
| PCSA Processa Pharmaceuticals Inc. Common Stock | $7.09M | — | $2.07 | ▼ 1.90% | $1.67$14.24 |
| ALZN Alzamend Neuro Inc. Common Stock | $6.42M | — | $1.66 | ▼ 0.30% | $0.84$2.68 |
| TRAW Traws Pharma Inc. Common Stock | $7.18M | — | $0.59 | ▲ 0.00% | $0.4301$3.27 |
| APUS Apimeds Pharmaceuticals US Inc. Common Stock | $7.32M | — | $3.87 | ▼ 1.28% | $3.39$403.1 |
| APRE Aprea Therapeutics Inc. Common stock | $7.40M | — | $0.8387 | ▼ 2.48% | $0.548$1.69 |
| ACXP Acurx Pharmaceuticals Inc. Common Stock | $6.15M | — | $1.45 | ▼ 1.03% | $1.31$8.34 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Can-Fite BioPharma Announces New Preclinical Findings Demonstrating Namodenoson Enhances Anti-Cancer Effect Of Gemcitabine Chemotherapy In Pancreatic CancerBenzinga · 8/17/2026
- Can-Fite BioPharma Submits Phase 2 Clinical Study Protocol To Bambino Gesù Children's Hospital In Rome, Italy, For First Clinical Evaluation Of Piclidenoson In Patients With Lowe SyndromeBenzinga · 8/3/2026
Insider Activity
Insider Actions →Acquired
48.0K
Disposed
0
- Farbstein Motti · June 4, 2026 · Grant24.0K
- Fishman Pnina · June 4, 2026 · Grant24.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 138.3K
- Total value held
- $328.7K
- Institutional holders
- 14
Top holders this quarter
- Unknown42.6K
- Unknown34.1K
- Unknown20.9K
- Unknown19.4K
- Unknown12.9K
- Unknown5.5K
- Unknown2.2K
- Unknown450
- Unknown150
- Unknown125
See the full, filterable feed with live charts on the MarketWall dashboard.